At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Nab-paclitaxel Combined With Bevacizumabdrug
Likely dose
Nab-paclitaxel Combined With Bevacizumab 150mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Non-randomized, Multicenter, Phase II Study of Nab-paclitaxel Combined with Bevacizumab for Unresectable Recurrent or Metastatic Extrapulmonary Neuroendocrine Carcinoma
In Brief
A Phase 2 clinical trial evaluating Nab-paclitaxel Combined With Bevacizumab for Neuroendocrine Carcinoma. Completed, enrolled 79 participants across 1 site.
Detailed Summary
This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel Combined With Bevacizumab for unresectable Recurrent or metastatic extrapulmonary neuroendocrine carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Carcinoma
CountriesChina
CollaboratorsQilu Pharmaceutical Co., Ltd.
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJan 2021
First PostedJan 2021
Primary CompletionSep 2024
TodayJul 2026
First PostedJan 12, 2021
Enrollment StartJan 5, 2021
Primary CompletionSep 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 5.5 years ago
Interventions
Nab-paclitaxel Combined With Bevacizumabdrug
Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.